Scott Ely - Concepedia

Author

Scott Ely

Cornell University ORCID

Also Known As

S Ely, S. Ely, SF Ely, Sandra Swain, Scooter Willis, Scott A Ely, Scott A. Ely, Scott Ely

142

Publications

Citations

H-Index

Concepts

All Affiliations

Cornell University NewYork–Presbyterian Hospital Presbyterian Hospital New York Hospital Queens Memorial Sloan Kettering Cancer Center

About

Scott Ely is an author at Cornell University specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.1K
2	Cell Biology	5	5	786
3	Health Sciences	3	3	68
4	Allergy	1	1	50
5	Cellular Physiology	1	1	107

Scott Ely

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus Ornella Flore, Shahin Rafii, Scott Ely, Nature Endothelial Cell PathobiologyViral PathogenesisPathologyVirologyHerpesviruses	1998	403
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma Peter Martin, Amy Chadburn, Paul J. Christos, Journal of Clinical Oncology	2009	335
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma Jia Ruan, Peter Martin, Richard R. Furman, Journal of Clinical Oncology	2010	317
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma John P. Leonard, Ann S. LaCasce, Mitchell R. Smith, Blood	2012	291
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma David Chiron, Maurizio Di Liberto, Peter Martin, Cancer Discovery	2014	271
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma John P. Leonard, Morton Coleman, Jamie Ketas, Journal of Clinical Oncology	2003	252
A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6 Linda B. Baughn, Maurizio Di Liberto, Kaida Wu, Cancer Research	2006	222
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Rubén Niesvizky, David Jayabalan, Paul J. Christos, Blood	2007	182
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation Achim A. Jungbluth, Scott Ely, Maurizio DiLiberto, Blood	2005	180
Expression of CD56/Neural Cell Adhesion Molecule Correlates with the Presence of Lytic Bone Lesions in Multiple Myeloma and Distinguishes Myeloma from Monoclonal Gammopathy of Undetermined Significance and Lymphomas with Plasmacytoid Differentiation Scott Ely, Daniel M. Knowles American Journal Of Pathology Hematological MalignancyNeuro-oncologyLymphoid NeoplasiaLytic Bone LesionsMalignant Blood Disorder	2002	172

Page 1